Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / SLC25A16



This biomarker is also known as:
  • solute carrier family 25 member 16,
  • solute carrier family 25 (mitochondrial carrier; Graves disease autoantigen), member 16,
  • Graves disease autoantigen,
  • Solute carrier family 25 member 16,
  • ML7,
  • graves disease carrier protein,
  • graves disease autoantigen,
  • hML7,
  • GDC,
  • mitochondrial solute carrier protein homolog,
  • D10S105E,
  • Mitochondrial solute carrier protein homolog,
  • HGT.1,
  • GDA,

View in BioMuta


SLC25A16 is a member of the mitochondrial carrier family and contains three tandemly repeated mitochondrial carrier protein domains. The SLC26A16 protein is found in the inner membrane of the mitochondria where it is necessary for the accumulation of coenzyme A in the mitochondrial matrix. SLC25A16 also facilitates the rapid transport and exchange of molecules between the cytosol and the mitochondrial matrix space. The SLC25A16 gene is thought to be involved in Graves' disease.


QA State: Curated
Type: Protein
Short Name:
HGNC Name: SLC25A16


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


No additional breast data available.

Performance Comment

ADH5 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.